Cargando…

P1006: CHARACTERIZATION OF TL-895: A NOVEL BRUTON TYROSINE KINASE INHIBITOR (BTKI) IN CLINICAL DEVELOPMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND MYELOFIBROSIS (MF)

Detalles Bibliográficos
Autores principales:	Gulrajani, Michael, Clevenger, Tracy, Cheung, Jean, Krantz, Fanny, Nguyen, Cynthia, Luarca, Miranda, Krejsa, Cecile, Rothbaum, Wayne P., Covey, Todd
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431306/ http://dx.doi.org/10.1097/01.HS9.0000970928.41702.a0

Ejemplares similares

P991: ADDING NAVTEMADLIN (NVTM) TO RUXOLITINIB (RUX) POTENTIATES APOPTOSIS IN MYELOBLASTS FROM PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
por: Clevenger, Tracy, et al.
Publicado: (2023)

P1005: EFFECT OF TL-895, A NOVEL BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ON ONCOGENIC JANUS KINASE 2-V617F (JAK2VF) SIGNALING
por: Chary Nimmagadda, Subbaiah, et al.
Publicado: (2023)

PB2198: TRIAL IN PROGRESS: AN OPEN-LABEL, GLOBAL, MULTICENTER, PHASE 1B/2 STUDY OF TL-895, A BRUTON’S TYROSINE KINASE INHIBITOR (BTKI), ADDED TO RUXOLITINIB (RUX) IN PATIENTS (PTS) WITH MYELOFIBROSIS (MF)
por: Palandri, Francesca, et al.
Publicado: (2023)

P1038: TL-895, A FIRST-IN-CLASS, COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) FOR THE TREATMENT OF MYELOFIBROSIS (MF) PATIENTS (PTS) WITH SEVERE THROMBOCYTOPENIA (PLATELETS (PLTS) <50 K/UL)
por: Loschi, Michael, et al.
Publicado: (2023)

PB2200: FOOD AND ACID REDUCING AGENT EFFECTS ON PHARMACOKINETICS (PK) AND PHARMACODYNAMICS (PD) OF THE COVALENT BRUTON TYROSINE KINASE INHIBITOR (BTKI) TL-895 IN HEALTHY SUBJECTS
por: Allard, Martine, et al.
Publicado: (2023)

PB2205: A MECHANISTIC ABSORPTION AND PHARMACOKINETIC MODEL OF COVALENT BTK INHIBITOR TL-895: INFLUENCE OF FOOD AND ACID REDUCING AGENTS
por: Macwan, Joyce, et al.
Publicado: (2023)

Harnessing the Effects of BTKi on T Cells for Effective Immunotherapy against CLL
por: Mhibik, Maissa, et al.
Publicado: (2019)

Targeting Bruton’s Tyrosine Kinase in CLL
por: Ahn, Inhye E., et al.
Publicado: (2021)

CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Poster: CLL-140 Booster and BTKi Interruption Improve Response to SARS-CoV-2 Vaccine in Patients With CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Booster and Btki Interruption Improve Response to Sars-Cov-2 Vaccine in Patients with CLL
por: Bryer, Emily, et al.
Publicado: (2022)

Is a BTKi or BCL2i preferable for first “novel” therapy in CLL? The case for BTKis
por: Brem, Elizabeth A., et al.
Publicado: (2022)

PB2696: QUALITATIVE INTERVIEWS TO DESCRIBE BURDEN IN PATIENTS (PT) WITH THIRD-LINE OR LATER CLL/SLL WITH PRIOR EXPOSURE TO BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)
por: Priyadarshini, Masoom, et al.
Publicado: (2023)

P1696: ECONOMIC BURDEN IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) FOR PATIENTS WITH ≥2 PRIOR LINES OF THERAPY INCLUDING A BRUTON TYROSINE KINASE INHIBITOR (BTKI) AND/OR B-CELL LYMPHOMA 2 INHIBITOR (BCL2I)
por: Priyadarshini, Masoom, et al.
Publicado: (2023)

Is BTKi or BCL2i preferable as first novel therapy in patients with CLL? The case for BCL2i
por: Seymour, John F.
Publicado: (2022)

S214: DISEASE-MODIFYING ACTIVITY OF NAVTEMADLIN (NVTM) CORRELATED WITH SURVIVAL OUTCOMES IN JANUS KINASE INHIBITOR (JAKI) RELAPSED OR REFRACTORY (R/R) MYELOFIBROSIS (MF) PATIENTS (PTS)
por: Vachhani, Pankit, et al.
Publicado: (2023)

International consensus statement on the management of cardiovascular risk of Bruton’s tyrosine kinase inhibitors in CLL
por: Awan, Farrukh T., et al.
Publicado: (2022)

P1110: REAL-WORLD TREATMENT PATTERNS OF BRUTON TYROSINE KINASE INHIBITORS (BTKI) IN PATIENTS WITH MANTLE CELL LYMPHOMA (MCL) IN COMMUNITY ONCOLOGY PRACTICES IN THE UNITED STATES (US)
por: Shah, Bijal, et al.
Publicado: (2023)

Preclinical evidence for the effective use of TL-895, a highly selective and potent second-generation BTK inhibitor, for the treatment of B-cell malignancies
por: Goodstal, Samantha M., et al.
Publicado: (2023)

P1239: BRUTON TYROSINE KINASE (BTK) PROTEIN DEGRADER BGB-16673 IS LESS APT TO CAUSE, AND ABLE TO OVERCOME VARIABLE BTK RESISTANCE MUTATIONS COMPARED TO OTHER BTK INHIBITORS (BTKI)
por: Feng, Xiaoyu, et al.
Publicado: (2023)

PB1864: BRUIN CLL-321: A PHASE 3 OPEN-LABEL, RANDOMIZED STUDY OF PIRTOBRUTINIB VS INVESTIGATOR’S CHOICE OF IDELALISIB+RITUXIMAB OR BENDAMUSTINE+RITUXIMAB IN BTKI PRETREATED CLL/SLL (TRIAL IN PROGRESS)
por: Sharman, J. P., et al.
Publicado: (2022)

AIPSS‐MF machine learning prognostic score validation in a cohort of myelofibrosis patients treated with ruxolitinib
por: Duminuco, Andrea, et al.
Publicado: (2023)

Insight into the Physical Properties of Fluoro-Perovskites Compounds of Tl-Based TlMF(3) (M = Au, Ga) Compounds Studied for Energy Generation Utilizing the TB-MBJ Potential Approximation Approach
por: Khan, Hukam, et al.
Publicado: (2023)

Progress report on project PS 1006 continuous transfer
por: Krusche, A
Publicado: (1975)

Tixagevimab/Cilgavimab Pre-exposure Prophylaxis in Patients With Lymphoproliferative Disorders on BTKi
por: Zamprogna, Giulia, et al.
Publicado: (2023)

Pion-Deuteron Coherent Scattering at 895 MeV/c
por: Bradamante, Franco, et al.
Publicado: (1968)

895. Prediction of Occurrence for Surgical Site Infection in Infected Surgeries
por: de Souza, Flávio Henrique Batista, et al.
Publicado: (2020)

POS-895 Post-COVID viral dermatoses and lupus patients
por: SAKAY, A., et al.
Publicado: (2022)

S167: EFFICACY AND SAFETY OF LUSPATERCEPT FOR THE TREATMENT OF ANEMIA IN PATIENTS WITH MYELOFIBROSIS: RESULTS FROM THE ACE-536-MF-001 STUDY
por: Gerds, Aaron T., et al.
Publicado: (2023)

Thymus-leukemia (TL) antigens of the mouse. Analysis of TL mRNA and TL cDNA TL+ and TL- strains
Publicado: (1985)

Hypertension and incident cardiovascular events after next-generation BTKi therapy initiation
por: Chen, Sunnia T., et al.
Publicado: (2022)

Identification of six hub genes in mantle cell lymphoma patients with BTKi resistance
por: Liu, Shuozi, et al.
Publicado: (2022)

1006. Contraception, Pregnancy and ART in Women of Child-Bearing Years
por: Hasan, Hira, et al.
Publicado: (2020)

The supernova remnant SN 1006 as a Galactic particle accelerator
por: Giuffrida, Roberta, et al.
Publicado: (2022)

P1006: NEXT GENERATION SEQUENCING (NGS) IN PEDIATRIC MASTOCYTOSIS
por: Angi, A., et al.
Publicado: (2022)

Bruton's tyrosine kinase: oncotarget in myeloma
por: Tai, Yu-Tzu, et al.
Publicado: (2012)

Editorial: Targeting Bruton Tyrosine Kinase
por: Brunner, Cornelia, et al.
Publicado: (2022)

Prospective analysis of 895 patients on a UK Genomics Review Board
por: Moore, David Allan, et al.
Publicado: (2019)

Tumor-Induced Osteomalacia: A Systematic Clinical Review of 895 Cases
por: Bosman, Ariadne, et al.
Publicado: (2022)

P53 autoantibodies in 1006 patients followed up for breast cancer
por: Metcalfe, Su, et al.
Publicado: (2000)

Cannot write session to /tmp/vufind_sessions/sess_h6asiq05g5bo54h1vau955468o